ASH 2026 focused update for adults with primary ITP conditionally recommends initial rituximab or a thrombopoietic agent plus corticosteroids over corticosteroids alone; after corticosteroid failure, a thrombopoietic agent (strong) or rituximab (conditional).
Guideline
Cuker et al. American Society of Hematology 2026 guidelines for immune thrombocytopenia: initial and second-line therapy for adults with primary ITP